Tetrazolium artifactually indicates superoxide dismutase-induced salvage in reperfused rabbit heart.
We tested the ability of a single dose of superoxide dismutase to induce salvage of reperfused rabbit myocardium. Infarct size was measured by tetrazolium method following 3, 24, or 72 h of reperfusion. In addition, the 24 h reperfused hearts were examined to determine if the drug induced salvage in those hearts was reflected in the histology. A coronary arterial branch was occluded for 45 min and then allowed to reperfuse for 3, 24 or 72 h. At the end of the reperfusion period the hearts were removed, perfusion stained with triphenyl tetrazolium, and fixed in buffered formalin. The hearts were sectioned and infarct size was determined in all groups. In addition, the 24 h heart slices were prepared for histology with H&E staining. The results revealed that 5 mg/kg hSOD treatment was associated with smaller infarcts in the 3 and 24 h groups but that differences were no longer apparent in the 72 h group. The 24 h control hearts showed good correlation between infarct size by TTC and that by conventional histology. In the 24 h treatment hearts, however, infarcts by TTC averaged only about 1/2 the size of those by conventional histology. We conclude that a single dose of hSOD fails to offer a sustained reduction of infarct size. Furthermore, histology from the 24 h reperfused group revealed that hSOD did not delay the onset of necrosis but rather simply caused dead tissue to retain its ability to reduce the tetrazolium salts.
Shirato
C
C
Department of Physiology, University of South Alabama, Mobile 36688.
Miura
T
T
Ooiwa
H
H
Toyofuku
T
T
Wilborn
W H
WH
Downey
J M
JM
D000818:Animals; D005189:False Positive Reactions; D006321:Heart / Q000187:drug effects / Q000503:physiopathology; D006439:Hemodynamics; D009203:Myocardial Infarction / Q000188:drug therapy / Q000473:pathology*; D015425:Myocardial Reperfusion; D009206:Myocardium / Q000473:pathology*; D009336:Necrosis; D011817:Rabbits; D011994:Recombinant Proteins / Q000494:pharmacology; D013194:Staining and Labeling; D013482:Superoxide Dismutase / Q000494:pharmacology* / Q000627:therapeutic use; D013778:Tetrazolium Salts; D013997:Time Factors
D011994:Recombinant Proteins; D013778:Tetrazolium Salts; C009591:triphenyltetrazolium; D013482:Superoxide Dismutase